JP2019531259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531259A5 JP2019531259A5 JP2019502696A JP2019502696A JP2019531259A5 JP 2019531259 A5 JP2019531259 A5 JP 2019531259A5 JP 2019502696 A JP2019502696 A JP 2019502696A JP 2019502696 A JP2019502696 A JP 2019502696A JP 2019531259 A5 JP2019531259 A5 JP 2019531259A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- pharmaceutical composition
- item
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 206010015943 Eye inflammation Diseases 0.000 claims description 2
- 206010029113 Neovascularisation Diseases 0.000 claims description 2
- 206010030043 Ocular hypertension Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 201000011190 diabetic macular edema Diseases 0.000 claims description 2
- 230000004406 elevated intraocular pressure Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 102000002090 Fibronectin type III Human genes 0.000 claims 3
- 108050009401 Fibronectin type III Proteins 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000738772 Homo sapiens Receptor-type tyrosine-protein phosphatase beta Proteins 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 106
- 238000000034 method Methods 0.000 description 20
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
- 102100037424 Receptor-type tyrosine-protein phosphatase beta Human genes 0.000 description 5
- 101710101345 Receptor-type tyrosine-protein phosphatase beta Proteins 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022075926A JP2022101694A (ja) | 2016-07-20 | 2022-05-02 | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
| JP2024186570A JP2025011323A (ja) | 2016-07-20 | 2024-10-23 | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662364381P | 2016-07-20 | 2016-07-20 | |
| US62/364,381 | 2016-07-20 | ||
| US201662377072P | 2016-08-19 | 2016-08-19 | |
| US62/377,072 | 2016-08-19 | ||
| PCT/US2017/042855 WO2018017714A1 (en) | 2016-07-20 | 2017-07-19 | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020120521A Division JP2020180156A (ja) | 2016-07-20 | 2020-07-14 | ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体 |
| JP2022075926A Division JP2022101694A (ja) | 2016-07-20 | 2022-05-02 | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531259A JP2019531259A (ja) | 2019-10-31 |
| JP2019531259A5 true JP2019531259A5 (enExample) | 2020-08-27 |
| JP7107914B2 JP7107914B2 (ja) | 2022-07-27 |
Family
ID=60988231
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502696A Active JP7107914B2 (ja) | 2016-07-20 | 2017-07-19 | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
| JP2020120521A Pending JP2020180156A (ja) | 2016-07-20 | 2020-07-14 | ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体 |
| JP2022075926A Pending JP2022101694A (ja) | 2016-07-20 | 2022-05-02 | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
| JP2024186570A Pending JP2025011323A (ja) | 2016-07-20 | 2024-10-23 | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020120521A Pending JP2020180156A (ja) | 2016-07-20 | 2020-07-14 | ＶＥ−ＰＴＰ（ＨＰＴＰ−β）を標的化するヒト化モノクローナル抗体 |
| JP2022075926A Pending JP2022101694A (ja) | 2016-07-20 | 2022-05-02 | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
| JP2024186570A Pending JP2025011323A (ja) | 2016-07-20 | 2024-10-23 | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US10253094B2 (enExample) |
| EP (1) | EP3487518A4 (enExample) |
| JP (4) | JP7107914B2 (enExample) |
| KR (1) | KR20190031246A (enExample) |
| CN (1) | CN109715189B (enExample) |
| AU (2) | AU2017299581B2 (enExample) |
| BR (1) | BR112019001206A2 (enExample) |
| CA (1) | CA3030298A1 (enExample) |
| IL (1) | IL263936A (enExample) |
| MX (1) | MX2019000727A (enExample) |
| PH (1) | PH12019500145A1 (enExample) |
| SG (2) | SG10201912556VA (enExample) |
| WO (1) | WO2018017714A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643469T3 (es) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| ES2774972T3 (es) * | 2011-10-13 | 2020-07-23 | Aerpio Therapeutics Inc | Tratamiento de enfermedades oculares |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| EP3471767A4 (en) | 2016-06-15 | 2020-01-15 | Icahn School of Medicine at Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| CA3030298A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.) |
| US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| EP3810634A4 (en) | 2018-06-21 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| KR20210061350A (ko) * | 2018-08-20 | 2021-05-27 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 폴리펩티드 |
| CN120058958A (zh) | 2018-09-24 | 2025-05-30 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| CA3121573A1 (en) | 2018-12-03 | 2020-06-11 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof |
| CA3137160A1 (en) * | 2019-04-24 | 2020-10-29 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| GB2589400A (en) | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
| CA3160148A1 (en) * | 2019-11-06 | 2021-05-14 | Northwestern University | Inhibition of the ve-ptp phosphatase protects the kidney from ischemia-reperfusion injury |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| JP2002540165A (ja) | 1999-03-26 | 2002-11-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔｉｅ２レセプターアクチベーターによる血管透過性の調節 |
| EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
| US20020068066A1 (en) * | 1999-08-20 | 2002-06-06 | Wenyuan Shi | Method for the treatment and prevention of dental caries |
| ATE363291T1 (de) | 2000-06-23 | 2007-06-15 | Bayer Schering Pharma Ag | Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren |
| KR20110025239A (ko) | 2001-09-28 | 2011-03-09 | 산텐 세이야꾸 가부시키가이샤 | 약물-폴리에틸렌글리콜 결합체를 함유하는 안조직 내 주입제 |
| US20050260132A1 (en) | 2001-10-17 | 2005-11-24 | Daniel Chin | Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta |
| DE60217711T2 (de) | 2001-12-04 | 2007-11-15 | Develogen Aktiengesellschaft | Ptp10d nukleinsäuren und peptide in der regulation von energie-homeostase |
| US20030215899A1 (en) | 2002-02-13 | 2003-11-20 | Ceptyr, Inc. | Reversible oxidation of protein tyrosine phosphatases |
| US20040023880A1 (en) | 2002-05-03 | 2004-02-05 | Gale Nicholas W. | Methods of inducing formation of functional and organized lymphatic vessels |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| WO2006091209A2 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007041317A2 (en) | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| EP3168234A1 (en) | 2005-12-15 | 2017-05-17 | Medimmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| EP1981520A2 (en) | 2006-01-30 | 2008-10-22 | (OSI) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
| AU2007226696C1 (en) * | 2006-03-10 | 2016-02-04 | Wyeth Llc | Anti-5T4 antibodies and uses thereof |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| ES2643469T3 (es) * | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| JP2010531896A (ja) | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| WO2009154026A1 (ja) * | 2008-06-20 | 2009-12-23 | 国立大学法人岡山大学 | 石灰化小球に対する抗体及びその用途 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| WO2010060748A1 (en) | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| BRPI1006898A2 (pt) | 2009-01-12 | 2015-09-08 | Akebia Therapeutics Inc | métodos de tratamento da síndrome do extravasamento vascular. |
| WO2010097800A1 (en) | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Synergistic combination of bioactive compounds for lowering of intraocular pressure |
| CA2756186A1 (en) * | 2009-03-24 | 2010-09-30 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against light and uses thereof |
| MY160399A (en) | 2009-07-06 | 2017-03-15 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| WO2011069019A2 (en) * | 2009-12-02 | 2011-06-09 | David Ho | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| US20120129847A1 (en) | 2010-10-07 | 2012-05-24 | Kevin Gene Peters | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| CA2827082A1 (en) | 2011-02-11 | 2012-08-16 | Psivida Us, Inc. | Methods of treating macular edema using antiedema therapeutics |
| CN107936121B (zh) * | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| ES2774972T3 (es) | 2011-10-13 | 2020-07-23 | Aerpio Therapeutics Inc | Tratamiento de enfermedades oculares |
| MX361337B (es) | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| ES3023054T3 (en) | 2012-11-08 | 2025-05-29 | Clearside Biomedical Inc | Methods for the treatment of ocular disease in human subjects |
| GB2516561B (en) | 2013-03-15 | 2016-03-09 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| WO2014203183A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating macular edema |
| EP3010525A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating choroidal neovascularisation |
| KR20160030504A (ko) | 2013-07-11 | 2016-03-18 | 노파르티스 아게 | 미숙아 망막병증의 치료에 있어서 vegf 길항제의 용도 |
| WO2015004616A1 (en) | 2013-07-11 | 2015-01-15 | Novartis Ag | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| EP3057990B1 (en) | 2013-10-18 | 2019-09-04 | Regeneron Pharmaceuticals, Inc. | Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| EP3092253B1 (en) | 2014-01-10 | 2021-03-17 | AnaptysBio, Inc. | Antibodies directed against interleukin-33 (il-33) |
| WO2015109898A1 (zh) | 2014-01-24 | 2015-07-30 | 上海恒瑞医药有限公司 | VEGF与PDGFRβ双特异性融合蛋白及其用途 |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| US9719135B2 (en) * | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
| US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
| EA201790236A1 (ru) | 2014-09-16 | 2017-11-30 | Оувэсайенс, Инк. | Антитела против vasa и способы их получения и использования |
| WO2016049183A1 (en) | 2014-09-24 | 2016-03-31 | Aerpio Therapeutics, Inc. | Ve-ptp extracellular domain antibodies delivered by a gene therapy vector |
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| AU2016240220B2 (en) | 2015-04-02 | 2019-11-21 | Molecular Partners Ag | Designed ankyrin repeat domains with binding specificity for serum albumin |
| WO2017035430A2 (en) | 2015-08-27 | 2017-03-02 | Kolltan Pharmaceuticals, Inc. | Anti-alk antibodies and methods for use thereof |
| CN116987187A (zh) | 2015-09-23 | 2023-11-03 | 豪夫迈·罗氏有限公司 | 抗-vegf抗体的优化的变体 |
| MY194736A (en) | 2015-09-23 | 2022-12-15 | Aerpio Therapeutics Inc | Methods of treating intraocular pressure with activators of tie-2 |
| WO2017165681A1 (en) | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
| CA3030298A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.) |
| CN120058958A (zh) | 2018-09-24 | 2025-05-30 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
-
2017
- 2017-07-19 CA CA3030298A patent/CA3030298A1/en active Pending
- 2017-07-19 SG SG10201912556VA patent/SG10201912556VA/en unknown
- 2017-07-19 BR BR112019001206A patent/BR112019001206A2/pt not_active Application Discontinuation
- 2017-07-19 AU AU2017299581A patent/AU2017299581B2/en active Active
- 2017-07-19 EP EP17831790.5A patent/EP3487518A4/en active Pending
- 2017-07-19 US US15/654,289 patent/US10253094B2/en active Active
- 2017-07-19 JP JP2019502696A patent/JP7107914B2/ja active Active
- 2017-07-19 KR KR1020197002479A patent/KR20190031246A/ko not_active Ceased
- 2017-07-19 MX MX2019000727A patent/MX2019000727A/es unknown
- 2017-07-19 CN CN201780057896.9A patent/CN109715189B/zh active Active
- 2017-07-19 SG SG11201900464TA patent/SG11201900464TA/en unknown
- 2017-07-19 WO PCT/US2017/042855 patent/WO2018017714A1/en not_active Ceased
-
2018
- 2018-11-05 US US16/180,854 patent/US10597452B2/en active Active
- 2018-11-05 US US16/180,850 patent/US10604569B2/en active Active
- 2018-12-24 IL IL263936A patent/IL263936A/en unknown
-
2019
- 2019-01-18 PH PH12019500145A patent/PH12019500145A1/en unknown
-
2020
- 2020-01-29 US US16/775,860 patent/US11136389B2/en active Active
- 2020-04-17 US US16/851,420 patent/US11180551B2/en active Active
- 2020-07-14 JP JP2020120521A patent/JP2020180156A/ja active Pending
-
2022
- 2022-05-02 JP JP2022075926A patent/JP2022101694A/ja active Pending
- 2022-05-27 US US17/804,396 patent/US12145986B2/en active Active
-
2024
- 2024-08-15 AU AU2024205789A patent/AU2024205789A1/en active Pending
- 2024-10-23 JP JP2024186570A patent/JP2025011323A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531259A5 (enExample) | ||
| Avery et al. | Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration | |
| Kovach et al. | Anti‐VEGF treatment strategies for wet AMD | |
| IL277215B1 (en) | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis | |
| CA2981145C (en) | Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused | |
| JP2010528047A5 (enExample) | ||
| CN120058958A (zh) | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 | |
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| JP2017536414A5 (enExample) | ||
| JP2017535285A5 (enExample) | ||
| JP2016536369A5 (enExample) | ||
| RU2012131251A (ru) | Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз | |
| WO2014062659A4 (en) | Methods of treating ocular diseases | |
| JP2017536391A (ja) | Ｉｌ−６ｒアンタゴニストを投与することによってドライアイ疾患を治療するための方法 | |
| JPWO2020068653A5 (enExample) | ||
| JP2019535651A5 (enExample) | ||
| Frampton | Aflibercept for intravitreal injection: in neovascular age-related macular degeneration | |
| CN103764830A (zh) | 含有irs-1抑制剂和vegf抑制剂的组合物 | |
| CN108602879A (zh) | 用于治疗疾病的抗体-药物协同作用技术 | |
| MX2020007948A (es) | Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular. | |
| AR079683A1 (es) | Formulacion topica oftalmica de peptidos | |
| Sawada et al. | Retinal vein occlusion | |
| JPWO2020092881A5 (enExample) | ||
| JP2011503094A5 (enExample) | ||
| JP2009538916A5 (enExample) |